Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338

 Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338

Shots:

  • AstraZeneca to receive option exercise fee in cash and equity, up to $162M as development & commercial milestones and royalties on global sales
  • Aevi Genomic to get an option to develop & commercialize AstraZeneca’s MEDI2338 and have to exercise the option within five mos. from the effective date of the agreement and will be responsible for clinical & commercial activities and costs. Exercising the option is contingent on Aevi securing additional funding
  • MEDI2338 is mAb targeting IL-18 and Aevi Genomics plans to initially develop MEDI2338 for adult onset Still’s disease (AOSD) and will further develop for other autoinflammatory disorders

Click here to­ read full press release/ article | Ref: Aevi Genomic Medicines | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post